Bio Roundup: CAR-T’s Huge Week, Merck’s ‘Pib Choice & More – Xconomy
Xconomy |
Bio Roundup: CAR–T's Huge Week, Merck's 'Pib Choice & More
Xconomy The far-out idea of reprogramming a patient's immune cells to fight cancer, known as CAR–T, entered the mainstream this week, and two numbers highlight the tale. The first is $11.9 billion, the price Gilead Sciences is paying for Kite Pharma and its … Gilead's Acquisition Of Kite Pharma Relieves Shareholders' Ennui |
